Chronic News and Research

RSS

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).

27 May 2009

1 in 7 Australians over 25 have chronic kidney disease

The latest report from the Australian Institute of Health and Welfare (AIHW) says between 2006 and 2007 more than a million hospital admissions in Australia were due to chronic kidney disease which was also a contributing factor in one in 10 deaths in 2006.

26 May 2009

Activated stem cells in damaged lungs could be first step toward cancer

Stem cells that respond after a severe injury in the lungs of mice may be a source of rapidly dividing cells that lead to lung cancer, according to a team of American and British researchers.

26 May 2009

Cancer drug capecitabine causes patient to lose fingerprints and be detained by U.S. immigration

Immigration officials held a cancer patient for four hours before they allowed him to enter the USA because one of his cancer drugs caused his fingerprints to disappear. His oncologist is now advising all cancer patients who are being treated with the commonly used drug, capecitabine, to carry a doctor's letter with them if they want to travel to the USA.

26 May 2009

The future of migraine: beyond just another pill

Patients living with migraine have strong reason for new optimism concerning a positive future. Two review articles and an accompanying editorial, "The Future of Migraine: Beyond Just Another Pill," in the current issue of Mayo Clinic Proceedings, are the basis for an ironic premise.

26 May 2009

Active ingredient in green tea shows promise in leukemia trials

Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea.

26 May 2009

Novel chemotherapy and biological agents brings dramatic increase in metastatic colon cancer survival

Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.

26 May 2009

Discovery of biological markers that may indicate poor breast cancer prognosis

A team of researchers has found an association between breast cancer survival and two proteins that, when present in the blood in high levels, are indicators of inflammation.

26 May 2009

Hospital refuses admission to young adults with thalassemia and sickle cell disease

Young adults with thalassemia and sickle cell diease have been trying for up to 10 years to gain admission to the only adult hospital program in central and southwestern Toronto specialized to treat their blood disorders. Since 1999, the Toronto General Hospital (TGH) has restricted the inherited blood disorders program to 99 patients requiring blood transfusions. As a result, about 150 young adults with complex disorders receive blood transfusions at the Hospital for Sick Children but no adult services.

25 May 2009

Discovery of genetic link between periodontitis and heart attack

The relationship between the dental disease periodontitis and coronary heart disease (CHD) has been known for several years. Although a genetic link seemed likely, until now its existence was uncertain. Now, for the first time, scientists have discovered a genetic relationship between the two conditions, a researcher told the annual conference of the European Society of Human Genetics today (Monday 25 May).

25 May 2009

Development of innovative nanotechnology drug delivery system for the treatment of pain

Z-Cube Srl, the corporate venture arm of Zambon Company SpA, and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today that they have entered into a license agreement for Z-Cube to develop and commercialize an innovative nanotechnology drug delivery system for the treatment of pain.

25 May 2009

Researchers unlock mystery of potentially fatal reaction to smallpox vaccine

Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine.

25 May 2009

Call for vaccination against HPV 16 in young men and women to prevent head and neck cancers

Researchers at Roswell Park Cancer Institute (RPCI) in Buffalo, New York, are strongly advocating a national discussion about the need to vaccinate both young men and women against HPV 16 to prevent head & neck cancers.

22 May 2009

Tuberculosis can evade immune response

Current research suggests that Mycobacterium tuberculosis can evade the immune response. The related report by Rahman et al, "Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory T cells in the granulomatous lesions," appears in the June 2009 issue of The American Journal of Pathology.

22 May 2009

Novel method stimulates growth of new neurons in adult brain

University at Buffalo researchers have identified a new mechanism that plays a central role in adult brain stem cell development and prompts brain stem cells to differentiate into neurons.

21 May 2009

Study offers new insights into morphine-induced tolerance and increased pain sensitivity

A study published in the June issue of Anesthesiology has shown that a drug metabolite of the opioid morphine may be a key factor in the paradoxical increased sensitivity to pain caused by chronic morphine use. For the first time, this metabolite (called morphine-6 glucuronide, or M6G) was shown to act independently of the pain receptors typically targeted during morphine administration.

21 May 2009

ChemGenex’s Omacetaxine to be showcased in three oral oresentations at EHA

ChemGenex Pharmaceuticals Limited announced today that new data from two clinical studies and one pre-clinical study with omacetaxine will be presented at oral sessions during the forthcoming 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.

21 May 2009

Telemedicine may improve care for school children with diabetes

Type 1 diabetes is the most common chronic childhood disease. The management of this serious medical condition includes regular fingerstick glucose measurements, multiple daily injections of insulin, and frequent insulin dose adjustments. Because children spend a great deal of their time in school, school nurses often supervise medical decisions and diabetes care.

21 May 2009

COPD patients benefit from lifestyle program

Patients with moderate COPD were randomized to receive "usual care" or to undergo an interdisciplinary, community-based program (INTERCOM) that offered an intensive lifestyle moderation phase of four months, during which patients were instructed in detail to perform two 15-minute intervals of pleasurable walking or cycling, and offered instruction in other lifestyle changes such as nutrition and smoking cessation.

20 May 2009

Nanoparticles used to stimulate growth of new neurons in adult brain

University at Buffalo researchers have identified a new mechanism that plays a central role in adult brain stem cell development and prompts brain stem cells to differentiate into neurons.

20 May 2009